PatientsVille.com
Gastritis, Gastric Ulcer, and Duodenal Ulcer | Concomitant Therapy of H. Pylori
Gastritis, Gastric Ulcer, and Duodenal Ulcer research study
What is the primary objective of this study?
If we compare eradication rate of Helicobacter pylori divided to 4 groups: amoxicillin, rabeprazole, clarithromycin(AOC), amoxicillin, rabeprazole, metronidazole(AOM), treated with amoxicillin, rabeprazole for 5 day, followed by clarithromycin, metronidazole, rabeprazole for 5 days(sequential), amoxicillin, clarithromycin, metronidazole, rabeprazole(concomitant), then the eradication rate of concomitant group will be the highest.
Who is eligible to participate?
Inclusion Criteria: - patients infected with Helicobacter pylori Exclusion Criteria: - cancer - pregnancy - formerly treated with eradication
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Gastritis, Gastric Ulcer, and Duodenal Ulcer
Study Interventions
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Drug:amoxicillin, clarithromycin, metronidazole, rabeprazole
Study Arms
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
AOC groupAOC group: treated with amoxicillin, rabeprazole, clarithromycin for 7 days
AOM groupAOM group: treated with amoxicillin, rabeprazole, metronidazole for 7 days
Sequential groupSequential group: treated with amoxicillin, rabeprazole for 5 day, followed by clarithromycin, metronidazole, rabeprazole for 5 days
concomitant groupconcomitant group: treated with amoxicillin, clarithromycin, metronidazole, rabeprazole for 7 days
Study Status
Unknown status
Start Date: August 2013
Completed Date: February 2014
Phase: Phase 4
Type: Interventional
Design:
Primary Outcome: Evaluation of the efficacy of concomitant therapy for eradication of Helicobacter pylori
Secondary Outcome:
Study sponsors, principal investigator, and references
Principal Investigator:
Lead Sponsor: The Catholic University of Korea
Collaborator: Bucheon St. Mary's Hospital
More information:https://clinicaltrials.gov/show/NCT01922765
